November 6, 2017 Clinical proof for both the CyberKnife and TomoTherapy Systems: access to 100 presentations/posters is on the ESTRO site. The new Delivery Analysis Software program for the TomoTherapy System Delivery Analysis for the TomoTherapy Program recently received 510 clearance from the U.S. Food and Drug Administration , in conjunction with the CE Tag in europe. The Delivery Analysis software program is an innovative device that leverages the initial architecture of the TomoTherapy System to provide unprecedented usage of treatment delivery information. The software provides enhanced confidence in system functionality before every treatment, and actionable insights to greatly help ensure all remedies stay on track.The mean remaining ventricular ejection fraction at 12 months was 41.8 percent in the repair group and 37.5 percent in the alternative group. The proportion of surviving patients with a recurrence of moderate or severe mitral regurgitation at 12 a few months was significantly higher in the repair group than in the replacement group . In the fix group, the 12-month LVESVI was 64.9 ml per square meter in patients with recurrent mitral regurgitation versus 47.0 ml per square meter in those without recurrent mitral regurgitation . Within 12 months, three sufferers in the restoration group and non-e in the substitute group underwent mitral-valve reoperation . Composite and Death Cardiac End Point At 12 months, we observed no factor in cumulative mortality between the repair group and the replacement group .